Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor - PubMed (original) (raw)
Pharmacological characterization of receptor-activity-modifying proteins (RAMPs) and the human calcitonin receptor
S L Armour et al. J Pharmacol Toxicol Methods. 1999 Dec.
Abstract
Receptor-activity-modifying proteins (RAMPs) are a family of single transmembrane domain proteins shown to be important for the transport and ligand specificity of the calcitonin gene-related peptide (CGRP) receptor. In this report, we describe the analysis of pharmacological properties of the human calcitonin receptor (hCTR) coexpressed with different RAMPs with the use of the Xenopus laevis melanophore expression system. We show that coexpression of RAMP3 with human calcitonin receptor changed the relative potency of hCTR to human calcitonin (hCAL) and rat amylin. RAMP1 and RAMP2, in contrast, had little effect on the change of hCTR potency to hCAL or rat amylin. When coexpressed with RAMP3, hCTR reversed the relative potency by a 3.5-fold loss in sensitivity to hCAL and a 19-fold increase in sensitivity to rat amylin. AC66, an inverse agonist, produced apparent simple competitive antagonism of hCAL and rat amylin, as indicated by linear Schild regressions. The potency of AC66 was changed in the blockade of rat amylin but not hCAL responses with RAMP3 coexpression. The mean pK(B) for AC66 to hCAL was 9.4 +/- 0.3 without RAMP3 and 9.45 +/- 0.07 with RAMP3. For the antagonism of AC66 to rat amylin, the pK(B) was 9.25 +/- 0.15 without RAMP3 and 8.2 +/- 0.35 with RAMP3. The finding suggests that RAMP3 might modify the active states of calcitonin receptor in such a way as to create a new receptor phenotype that is "amylin-like." Irrespective of the physiological association of the new receptor species, the finding that a coexpressed membrane protein can completely change agonist and antagonist affinities for a receptor raises implications for screening in recombinant receptor systems.
Similar articles
- Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat.
Oliver KR, Kane SA, Salvatore CA, Mallee JJ, Kinsey AM, Koblan KS, Keyvan-Fouladi N, Heavens RP, Wainwright A, Jacobson M, Dickerson IM, Hill RG. Oliver KR, et al. Eur J Neurosci. 2001 Aug;14(4):618-28. doi: 10.1046/j.0953-816x.2001.01688.x. Eur J Neurosci. 2001. PMID: 11556887 - Specificity of porcine calcitonin receptor and calcitonin receptor-like receptor in the presence of receptor-activity-modifying proteins.
Kikumoto K, Katafuchi T, Minamino N. Kikumoto K, et al. Hypertens Res. 2003 Feb;26 Suppl:S15-23. doi: 10.1291/hypres.26.s15. Hypertens Res. 2003. PMID: 12630807 - Multiple ramp domains are required for generation of amylin receptor phenotype from the calcitonin receptor gene product.
Zumpe ET, Tilakaratne N, Fraser NJ, Christopoulos G, Foord SM, Sexton PM. Zumpe ET, et al. Biochem Biophys Res Commun. 2000 Jan 7;267(1):368-72. doi: 10.1006/bbrc.1999.1943. Biochem Biophys Res Commun. 2000. PMID: 10623626 - Functional relevance of G-protein-coupled-receptor-associated proteins, exemplified by receptor-activity-modifying proteins (RAMPs).
Fischer JA, Muff R, Born W. Fischer JA, et al. Biochem Soc Trans. 2002 Aug;30(4):455-60. doi: 10.1042/bst0300455. Biochem Soc Trans. 2002. PMID: 12196114 Review. - Receptor pharmacology.
Young A. Young A. Adv Pharmacol. 2005;52:47-65. doi: 10.1016/S1054-3589(05)52003-9. Adv Pharmacol. 2005. PMID: 16492540 Review.
Cited by
- Amylin receptor subunit interactions are modulated by agonists and determine signaling.
Gostynska SE, Karim JA, Ford BE, Gordon PH, Babin KM, Inoue A, Lambert NA, Pioszak AA. Gostynska SE, et al. bioRxiv [Preprint]. 2024 Oct 9:2024.10.09.617487. doi: 10.1101/2024.10.09.617487. bioRxiv. 2024. PMID: 39416010 Free PMC article. Preprint. - Multiplexed analysis of the secretin-like GPCR-RAMP interactome.
Lorenzen E, Dodig-Crnković T, Kotliar IB, Pin E, Ceraudo E, Vaughan RD, Uhlèn M, Huber T, Schwenk JM, Sakmar TP. Lorenzen E, et al. Sci Adv. 2019 Sep 18;5(9):eaaw2778. doi: 10.1126/sciadv.aaw2778. eCollection 2019 Sep. Sci Adv. 2019. PMID: 31555726 Free PMC article. - Molecular interaction of an antagonistic amylin analog with the extracellular domain of receptor activity-modifying protein 2 assessed by fluorescence polarization.
Lee S, Pioszak AA. Lee S, et al. Biophys Chem. 2020 Dec;267:106477. doi: 10.1016/j.bpc.2020.106477. Epub 2020 Sep 20. Biophys Chem. 2020. PMID: 33137565 Free PMC article. - h_CALCRL_ mutation causes autosomal recessive nonimmune hydrops fetalis with lymphatic dysplasia.
Mackie DI, Al Mutairi F, Davis RB, Kechele DO, Nielsen NR, Snyder JC, Caron MG, Kliman HJ, Berg JS, Simms J, Poyner DR, Caron KM. Mackie DI, et al. J Exp Med. 2018 Sep 3;215(9):2339-2353. doi: 10.1084/jem.20180528. Epub 2018 Aug 16. J Exp Med. 2018. PMID: 30115739 Free PMC article. - Calcitonin and bone formation: a knockout full of surprises.
Zaidi M, Moonga BS, Abe E. Zaidi M, et al. J Clin Invest. 2002 Dec;110(12):1769-71. doi: 10.1172/JCI17425. J Clin Invest. 2002. PMID: 12488426 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous